<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0cm;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Interesting article.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'><br><b>Subject:</b> Fwd: Fw: ASCO 2015 - Chemotherapy Use in Prostate Cancer: Early or Late?<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><div><p class=MsoNormal>FYI >From <a href="http://urotoday.com">urotoday.com</a><o:p></o:p></p><div><div><p class=MsoNormal> <o:p></o:p></p><div><div><div><div><div><p class=MsoNormal style='background:white'><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:black'>From:</span></b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:black'> UroToday <<a href="mailto:editors@urotoday.com" target="_blank">editors@urotoday.com</a>><br> <br><b>Subject:</b> ASCO 2015 - Chemotherapy Use in Prostate Cancer: Early or Late?</span><span style='font-family:"Helvetica","sans-serif";color:black'><o:p></o:p></span></p></div><div><p class=MsoNormal style='background:white'><span style='font-family:"Helvetica","sans-serif";color:black'><o:p> </o:p></span></p><div><div><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:whitesmoke'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=728 style='width:546.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='mso-line-height-alt:0pt'><a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=40985&mailid=2713&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=728 height=90 id="_x0000_i1025" src="http://digitalscience.rotator.hadj1.adjuggler.net/servlet/ajrotator/1597154/0/vc?z=digitalscience&dim=1387992&kw=&click=&session=no&ajkey="></span></a><o:p></o:p></p></td></tr></table></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt'><tr><td style='background:white;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='mso-line-height-alt:0pt'><a href="http://www.urotoday.com/index.php?option=com_content&Itemid=101&id=49023&lang=en&view=article" target="_blank"><span style='text-decoration:none'><img border=0 width=600 height=86 id="_x0000_i1026" src="http://www.urotoday.com/images/conferences/ASCO_2015/2015_ASCO_Banner_NowOnline.jpg" alt="spotlight header"></span></a><o:p></o:p></p></td></tr><tr><td valign=top style='background:white;padding:11.25pt 3.0pt 0cm 3.0pt'><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:19.5pt;color:#6B6B6B'>Chemotherapy Use in Prostate Cancer<o:p></o:p></span></p></div><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;color:#6B6B6B'>June 2, 2015<o:p></o:p></span></p></div><div class=MsoNormal align=center style='text-align:center'><hr size=2 width="100%" align=center></div></td></tr><tr><td style='background:white;padding:18.75pt 1.5pt 1.5pt 1.5pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=520 style='width:390.0pt'><tr><td style='background:#24959C;padding:3.75pt 15.0pt 3.75pt 15.0pt'><div><p class=MsoNormal align=center style='text-align:center;line-height:130%'><span style='font-size:15.0pt;line-height:130%;color:white'>Now or Later: Optimal Timing of Docetaxel for Metastatic Prostate Cancer<o:p></o:p></span></p></div></td></tr><tr><td valign=top style='border:solid #24959C 1.0pt;background:white;padding:15.0pt 15.0pt 15.0pt 15.0pt'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='margin-bottom:12.0pt'><img border=0 width=480 height=100 id="_x0000_i1028" src="cid:3aa6b1ca623a2d4500dfc5c0f392931d" alt="2 mds talking"><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#0D666C'>Early treatment with docetaxel chemotherapy </span><i><span style='font-size:10.5pt;line-height:140%;color:#0D666C'>(Presented by Maha Hussain, MB, ChB)</span></i><span style='color:#0D666C'><o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#0D666C;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=2516&option=com_content&view=article&catid=1680&id=81081&utm_source=newsletter_2713&utm_medium=email&utm_campaign=asco-2015-chemotherapy-use-in-prostate-cancer-early-or-late-060215&acm=13579_2713" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table><p class=MsoNormal style='margin-bottom:12.0pt'><br><br><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#0D666C'>Late treatment with docetaxel chemotherapy </span><i><span style='font-size:10.5pt;line-height:140%;color:#0D666C'>(Presented by Howard I. Scher, MD)</span></i><span style='color:#0D666C'><o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#0D666C;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=2516&option=com_content&view=article&catid=1680&id=81082&utm_source=newsletter_2713&utm_medium=email&utm_campaign=asco-2015-chemotherapy-use-in-prostate-cancer-early-or-late-060215&acm=13579_2713" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table><p class=MsoNormal style='margin-bottom:12.0pt'><br><br><o:p></o:p></p><div><p class=MsoNormal style='line-height:140%'><span style='color:#0D666C'>Bottom line: Timing of treatment with docetaxel for men with advanced prostate cancer </span><i><span style='font-size:10.5pt;line-height:140%;color:#0D666C'>(Presented by Howard I. Scher, MD and Maha Hussain, MB, ChB)</span></i><span style='color:#0D666C'><o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=130 style='width:97.5pt'><tr><td style='background:#0D666C;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?Itemid=2516&option=com_content&view=article&catid=1680&id=81092&utm_source=newsletter_2713&utm_medium=email&utm_campaign=asco-2015-chemotherapy-use-in-prostate-cancer-early-or-late-060215&acm=13579_2713" target="_blank"><span style='color:white;text-decoration:none'>Read More →</span></a><o:p></o:p></p></div></td></tr></table></td></tr></table></td></tr></table></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=280 style='width:210.0pt'><tr><td style='background:#F49B3C;padding:3.75pt 3.75pt 3.75pt 3.75pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/asco-2015.html?utm_source=newsletter_2713&utm_medium=email&utm_campaign=asco-2015-chemotherapy-use-in-prostate-cancer-early-or-late-060215&acm=13579_2713" target="_blank"><span style='color:white;text-decoration:none'>View all ASCO 2015 Highlights →</span></a><o:p></o:p></p></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><br> <o:p></o:p></p></td></tr><tr><td style='border:solid #80929E 1.0pt;background:#80929E;padding:11.25pt 0cm 5.25pt 0cm'><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=40986&mailid=2713&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1029" src="cid:10e354c32be72619fa8cc663f93029d8" alt=twitter></span></a> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=40987&mailid=2713&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1030" src="cid:3d31e488c1661908628ece569cffd49c" alt=facebook></span></a> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=40988&mailid=2713&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1031" src="cid:fdff0e671376f4630e2ee9c934c3cb3b" alt=linkedin></span></a> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=url&urlid=40989&mailid=2713&Itemid=1448" target="_blank"><span style='text-decoration:none'><img border=0 width=24 height=24 id="_x0000_i1032" src="cid:479b26af0c790ab4b716c3873e4ba30f" alt=youtube></span></a> <o:p></o:p></p></td></tr><tr><td style='border:solid #80929E 1.0pt;background:#80929E;padding:0cm 0cm 0cm 0cm'><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;color:white'>UroToday - 2217 Fifth Street, Berkeley, CA 94710 USA<o:p></o:p></span></p></div></td></tr><tr><td style='border:solid #80929E 1.0pt;background:#80929E;padding:3.75pt 0cm 6.0pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'><a href="http://www.urotoday.com/index.php?option=com_acymailing&ctrl=archive&task=view&mailid=2713&key=sxCYu5sm&subid=13579-e9ca2e4efd9e5bfe9e07c9e19072ee54&tmpl=component&Itemid=1448&utm_source=newsletter_2713&utm_medium=email&utm_campaign=asco-2015-chemotherapy-use-in-prostate-cancer-early-or-late-060215&acm=13579_2713" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>View Email in Browser |</span></a> <o:p></o:p></p></td><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'> <a href="http://www.urotoday.com/index.php?option=com_acymailing&view=user&layout=modify&Itemid=101" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>Manage Preferences |</span></a> <o:p></o:p></p></td><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'> <a href="http://www.urotoday.com/index.php?subid=13579&option=com_acymailing&ctrl=user&task=out&mailid=2713&key=e9ca2e4efd9e5bfe9e07c9e19072ee54&Itemid=1448" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>Unsubscribe</span></a> <span style='font-size:9.0pt;color:white'>|</span> <o:p></o:p></p></td><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'> <a href="http://www.urotoday.com/index.php?option=com_acymailing&ctrl=archive&task=forward&mailid=2713&key=sxCYu5sm&subid=13579-e9ca2e4efd9e5bfe9e07c9e19072ee54&Itemid=1448&utm_source=newsletter_2713&utm_medium=email&utm_campaign=asco-2015-chemotherapy-use-in-prostate-cancer-early-or-late-060215&acm=13579_2713" target="_blank"><span style='font-size:9.0pt;color:white;text-decoration:none'>Forward Email</span></a> <o:p></o:p></p></td></tr></table></div></td></tr><tr><td style='background:whitesmoke;padding:7.5pt 3.75pt 7.5pt 3.75pt'><p class=MsoNormal><span style='font-size:7.5pt'>You are receiving this email because you have chosen to receive emails from UroToday. <a href="http://www.urotoday.com/index.php?option=com_comprofiler&Itemid=473&utm_source=newsletter_2713&utm_medium=email&utm_campaign=asco-2015-chemotherapy-use-in-prostate-cancer-early-or-late-060215&acm=13579_2713" target="_blank"><b><span style='color:#4687E9;text-decoration:none'>Log in</span></b></a> to update your email address or view your email preferences. If you have any questions about your account, please log in to contact us securely and we will be happy to assist you.<o:p></o:p></span></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal style='background:white'><span style='font-family:"Helvetica","sans-serif";color:black'><img border=0 width=1 height=1 id="_x0000_i1033" src="https://449afirp.emltrk.com/449afirp?d=rochab2@yahoo.com"><img border=0 width=50 height=1 id="_x0000_i1034" src="http://www.urotoday.com/index.php?option=com_acymailing&ctrl=stats&mailid=2713&subid=13579&Itemid=1448"><o:p></o:p></span></p></div></div><p class=MsoNormal style='margin-bottom:12.0pt;background:white'><span style='font-family:"Helvetica","sans-serif";color:black'><o:p> </o:p></span></p></div></div></div></div></div></div><p class=MsoNormal><o:p> </o:p></p></div></div></div></body></html>